Sham Treatment
Gene therapy improves motor function in spinal muscular atrophy at 52 weeks
Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 weeks compared with sham in patients aged 2 to 18 years with spinal muscular atrophy, data show.
Intracranial frequency stimulation linked to improved memory, cognition in Alzheimer’s
Results from a clinical trial examining intracranial stimulation using a novel device in those with mild Alzheimer’s disease showed that treatment led to improvements in memory, cognitive function and blood flow.
High dose of novel PD gene therapy linked to improved outcomes at 26 weeks
Topline data from a phase 2 clinical trial of an investigational gene therapy for Parkinson’s disease showed that a higher dose of the medication significantly improved disease-specific and quality of life measures by week 26.
No significant improvement in cognition with active vs. sham transcranial stimulation
Researchers reported no significant difference in cognitive performance between active and sham transcranial direct current stimulation for mild cognitive impairment, per a poster at the Alzheimer’s Association International Conference.